Advertisement

Breast Cancer Research and Treatment

, Volume 153, Issue 1, pp 211–218 | Cite as

Breast cancer survival in African-American women by hormone receptor subtypes

  • Tomi AkinyemijuEmail author
  • Justin Xavier Moore
  • Sean F. Altekruse
Epidemiology

Abstract

Breast cancer accounts for over 200,000 annual cases among women in the United States, and is the second leading cause of cancer-related deaths. However, few studies have investigated the association between breast cancer subtype and survival among African-American women. We analyzed cancer-related deaths among African-American women using data obtained from the SEER database linked to the 2000 U.S. census data. We examined distribution of baseline socio-demographic and clinical characteristics by breast cancer subtypes and used Cox proportional hazard models to determine associations between breast cancer subtypes and cancer-related mortality, adjusting for age, socio-economic status, stage at diagnosis, and treatment. Among 19,836 female breast cancer cases, 54.4 % were diagnosed with the HER2−/HR+ subtype, with the majority of those cases occurring among women ages 55 and older. However, after adjusting for age, stage, and treatment type (surgery, radiation, or no radiation and/or cancer-directed surgery), TNBC (HR 2.34; 95 % CI 1.95–2.81) and HER2+/HR− (HR 1.39, 95 % CI 1.08–1.79) cases had significantly higher hazards of cancer-related deaths compared with HER2+/HR+ cases. Adjusting for socio-economic status did not significantly alter these associations. African-American women with TNBC were more likely to have a cancer-related death than African-American women with other breast cancer subtypes. This association remained after adjustments for age, stage, treatment, and socio-economic status. Further studies are needed to identify subtype-specific risk and prognostic factors aimed at better informing prevention efforts for all women.

Keywords

Breast cancer Hormone receptor subtype Triple negative African Americans Survival 

Notes

Compliance with ethical standards

Conflict of Interest

There are no conflicts of interest to declare.

References

  1. 1.
    DeSantis C, Ma J, Bryan L, Jemal A (2014) Breast cancer statistics, 2013. CA Cancer J Clin 64(1):52–62. doi: 10.3322/caac.21203 CrossRefPubMedGoogle Scholar
  2. 2.
    Howlander N, Noone AM, Krapcho M, Garshell j, Miller D, Altekruse SF, Kosary CL, Yu M (2015) Seer Cancer Statistics Review, 1975–2012. National Cancer Institute, Bethesda, MDGoogle Scholar
  3. 3.
    Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M (2006) Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 56(3):168–183CrossRefPubMedGoogle Scholar
  4. 4.
    Weir HK, Thun MJ, Hankey BF, Ries LA, Howe HL, Wingo PA, Jemal A, Ward E, Anderson RN, Edwards BK (2003) Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 95(17):1276–1299CrossRefPubMedGoogle Scholar
  5. 5.
    Keegan TH, Kurian AW, Gali K, Tao L, Lichtensztajn DY, Hershman DL, Habel LA, Caan BJ, Gomez SL (2015) Racial/ethnic and socioeconomic differences in short-term breast cancer survival among women in an integrated health system. Am J Public Health 105(5):938–946. doi: 10.2105/AJPH.2014.302406 CrossRefPubMedGoogle Scholar
  6. 6.
    Newman LA (2014) Breast cancer disparities: high-risk breast cancer and African ancestry. Surg Oncol Clin N Am 23(3):579–592. doi: 10.1016/j.soc.2014.03.014 CrossRefPubMedGoogle Scholar
  7. 7.
    Tammemagi CM, Nerenz D, Neslund-Dudas C, Feldkamp C, Nathanson D (2005) Comorbidity and survival disparities among black and white patients with breast cancer. JAMA 294(14):1765–1772. doi: 10.1001/jama.294.14.1765 CrossRefPubMedGoogle Scholar
  8. 8.
    Akinyemiju TF, Soliman AS, Johnson NJ, Altekruse SF, Welch K, Banerjee M, Schwartz K, Merajver S (2013) Individual and neighborhood socioeconomic status and healthcare resources in relation to black-white breast cancer survival disparities. J Cancer Epidemiol 2013:490472. doi: 10.1155/2013/490472 PubMedCentralPubMedGoogle Scholar
  9. 9.
    Akinyemiju TF, Soliman AS, Copeland G, Banerjee M, Schwartz K, Merajver SD (2013) Trends in breast cancer stage and mortality in Michigan (1992–2009) by race, socioeconomic status, and area healthcare resources. PLoS One 8(4):e61879. doi: 10.1371/journal.pone.0061879 PubMedCentralCrossRefPubMedGoogle Scholar
  10. 10.
    Joslyn SA, Foote ML, Nasseri K, Coughlin SS, Howe HL (2005) Racial and ethnic disparities in breast cancer rates by age: NAACCR Breast Cancer Project. Breast Cancer Res Treat 92(2):97–105. doi: 10.1007/s10549-005-2112-y CrossRefPubMedGoogle Scholar
  11. 11.
    Robbins HA, Engels EA, Pfeiffer RM, Shiels MS (2015) Age at cancer diagnosis for blacks compared with whites in the United States. J Natl Cancer Inst. doi: 10.1093/jnci/dju489 Google Scholar
  12. 12.
    Sail K, Franzini L, Lairson D, Du X (2012) Differences in treatment and survival among African-American and Caucasian women with early stage operable breast cancer. Ethn Health 17(3):309–323. doi: 10.1080/13557858.2011.628011 CrossRefPubMedGoogle Scholar
  13. 13.
    Yu XQ (2009) Socioeconomic disparities in breast cancer survival: relation to stage at diagnosis, treatment and race. BMC Cancer 9:364. doi: 10.1186/1471-2407-9-364 PubMedCentralCrossRefPubMedGoogle Scholar
  14. 14.
    Parise CA, Caggiano V (2014) Breast cancer survival defined by the ER/PR/HER2 subtypes and a surrogate classification according to tumor grade and immunohistochemical biomarkers. J Cancer Epidemiol 2014:469251. doi: 10.1155/2014/469251 PubMedCentralPubMedGoogle Scholar
  15. 15.
    Ihemelandu CU, Leffall LD Jr, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA (2007) Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res 143(1):109–118. doi: 10.1016/j.jss.2007.03.085 CrossRefPubMedGoogle Scholar
  16. 16.
    Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA (2014) US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. doi: 10.1093/jnci/dju055 PubMedGoogle Scholar
  17. 17.
    Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD Jr, Dewitty RL Jr, Frederick WA (2008) Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women. Am J Surg 195(2):153–158. doi: 10.1016/j.amjsurg.2007.09.033 CrossRefPubMedGoogle Scholar
  18. 18.
    Boyle P (2012) Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 23(Suppl 6):vi7–vi12. doi: 10.1093/annonc/mds187 CrossRefPubMedGoogle Scholar
  19. 19.
    Edge SB, Byrd, Compton CC, Fritz AG, Greene FL, Trotti A (2011) AJCC cancer staging manual, vol 7. Springer, New YorkGoogle Scholar
  20. 20.
    Tao L, Gomez SL, Keegan TH, Kurian AW, Clarke CA (2015) Breast cancer mortality in African-American and non-hispanic white women by molecular subtype and stage at diagnosis: a population-based study. Cancer Epidemiol Biomarkers Prev 24(7):1039–1045. doi: 10.1158/1055-9965.EPI-15-0243 CrossRefPubMedGoogle Scholar
  21. 21.
    Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109(9):1721–1728. doi: 10.1002/cncr.22618 CrossRefPubMedGoogle Scholar
  22. 22.
    Kurian AW, Fish K, Shema SJ, Clarke CA (2010) Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res 12(6):R99. doi: 10.1186/bcr2780 PubMedCentralCrossRefPubMedGoogle Scholar
  23. 23.
    Ma H, Lu Y, Malone KE, Marchbanks PA, Deapen DM, Spirtas R, Burkman RT, Strom BL, McDonald JA, Folger SG, Simon MS, Sullivan-Halley J, Press MF, Bernstein L (2013) Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status. BMC Cancer 13:225. doi: 10.1186/1471-2407-13-225 PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Kroenke CH, Sweeney C, Kwan ML, Quesenberry CP, Weltzien EK, Habel LA, Castillo A, Bernard PS, Factor RE, Kushi LH, Caan BJ (2014) Race and breast cancer survival by intrinsic subtype based on PAM50 gene expression. Breast Cancer Res Treat 144(3):689–699. doi: 10.1007/s10549-014-2899-5 PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Warner ET, Tamimi RM, Hughes ME, Ottesen RA, Wong YN, Edge SB, Theriault RL, Blayney DW, Niland JC, Winer EP, Weeks JC, Partridge AH (2015) Racial and ethnic differences in breast cancer survival: mediating effect of tumor characteristics and sociodemographic and treatment factors. J Clin Oncol 33(20):2254–2261. doi: 10.1200/JCO.2014.57.1349 CrossRefPubMedGoogle Scholar
  26. 26.
    Bradley CJ, Given CW, Roberts C (2002) Race, socioeconomic status, and breast cancer treatment and survival. J Natl Cancer Inst 94(7):490–496CrossRefPubMedGoogle Scholar
  27. 27.
    Cross CK, Harris J, Recht A (2002) Race, socioeconomic status, and breast carcinoma in the U.S: what have we learned from clinical studies. Cancer 95(9):1988–1999. doi: 10.1002/cncr.10830 CrossRefPubMedGoogle Scholar
  28. 28.
    Dai D (2010) Black residential segregation, disparities in spatial access to health care facilities, and late-stage breast cancer diagnosis in metropolitan Detroit. Health Place 16(5):1038–1052. doi: 10.1016/j.healthplace.2010.06.012 CrossRefPubMedGoogle Scholar
  29. 29.
    El-Tamer MB, Homel P, Wait RB (1999) Is race a poor prognostic factor in breast cancer? J Am Coll Surg 189(1):41–45CrossRefPubMedGoogle Scholar
  30. 30.
    Gwyn K, Bondy ML, Cohen DS, Lund MJ, Liff JM, Flagg EW, Brinton LA, Eley JW, Coates RJ (2004) Racial differences in diagnosis, treatment, and clinical delays in a population-based study of patients with newly diagnosed breast carcinoma. Cancer 100(8):1595–1604. doi: 10.1002/cncr.20169 CrossRefPubMedGoogle Scholar
  31. 31.
    Heimann R, Ferguson D, Powers C, Suri D, Weichselbaum RR, Hellman S (1997) Race and clinical outcome in breast cancer in a series with long-term follow-up evaluation. J Clin Oncol 15(6):2329–2337PubMedGoogle Scholar
  32. 32.
    Kim SH, Ferrante J, Won BR, Hameed M (2008) Barriers to adequate follow-up during adjuvant therapy may be important factors in the worse outcome for Black women after breast cancer treatment. World J Surg Oncol 6:26. doi: 10.1186/1477-7819-6-26 PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Li CI, Malone KE, Daling JR (2003) Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 163(1):49–56CrossRefPubMedGoogle Scholar
  34. 34.
    Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374. doi: 10.1158/1078-0432.CCR-04-0220 CrossRefPubMedGoogle Scholar
  35. 35.
    Vona-Davis L, Rose DP, Hazard H, Howard-McNatt M, Adkins F, Partin J, Hobbs G (2008) Triple-negative breast cancer and obesity in a rural Appalachian population. Cancer Epidemiol Biomarkers Prev 17(12):3319–3324. doi: 10.1158/1055-9965.EPI-08-0544 CrossRefPubMedGoogle Scholar
  36. 36.
    Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295(21):2492–2502. doi: 10.1001/jama.295.21.2492 CrossRefPubMedGoogle Scholar
  37. 37.
    Rakha EA, El-Rehim DA, Paish C, Green AR, Lee AH, Robertson JF, Blamey RW, Macmillan D, Ellis IO (2006) Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance. Eur J Cancer 42(18):3149–3156. doi: 10.1016/j.ejca.2006.08.015 CrossRefPubMedGoogle Scholar
  38. 38.
    Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874. doi: 10.1073/pnas.191367098 PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V (2008) The role of human epidermal growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-negative, invasive breast cancer: the California Cancer Registry, 1999–2004. Cancer 112(4):737–747. doi: 10.1002/cncr.23243 CrossRefPubMedGoogle Scholar
  40. 40.
    Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329–2334. doi: 10.1158/1078-0432.CCR-06-1109 CrossRefPubMedGoogle Scholar
  41. 41.
    Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. doi: 10.1038/35021093 CrossRefPubMedGoogle Scholar
  42. 42.
    Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, Nielsen TO (2008) Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res 14(5):1368–1376. doi: 10.1158/1078-0432.CCR-07-1658 CrossRefPubMedGoogle Scholar
  43. 43.
    Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland-Jones B, Brawley OW, Flagg EW, O’Regan RM, Gabram SG, Eley JW (2009) Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 113(2):357–370. doi: 10.1007/s10549-008-9926-3 CrossRefPubMedGoogle Scholar
  44. 44.
    Reis-Filho JS, Tutt AN (2008) Triple negative tumours: a critical review. Histopathology 52(1):108–118. doi: 10.1111/j.1365-2559.2007.02889.x CrossRefPubMedGoogle Scholar
  45. 45.
    Rakha EA, Ellis IO (2009) Triple-negative/basal-like breast cancer: review. Pathology 41(1):40–47. doi: 10.1080/00313020802563510 CrossRefPubMedGoogle Scholar
  46. 46.
    Maiti B, Kundranda MN, Spiro TP, Daw HA (2010) The association of metabolic syndrome with triple-negative breast cancer. Breast Cancer Res Treat 121(2):479–483. doi: 10.1007/s10549-009-0591-y CrossRefPubMedGoogle Scholar
  47. 47.
    Arslan C, Dizdar O, Altundag K (2009) Pharmacotherapy of triple-negative breast cancer. Expert Opin Pharmacother 10(13):2081–2093. doi: 10.1517/14656560903117309 CrossRefPubMedGoogle Scholar
  48. 48.
    Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353(16):1673–1684. doi: 10.1056/NEJMoa052122 CrossRefPubMedGoogle Scholar
  49. 49.
    Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ, HERA Study Team (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555):29–36. doi: 10.1016/S0140-6736(07)60028-2 CrossRefPubMedGoogle Scholar
  50. 50.
    Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L (2008) Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26(8):1275–1281. doi: 10.1200/JCO.2007.14.4147 CrossRefPubMedGoogle Scholar
  51. 51.
    Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L (2005) Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 11(16):5678–5685. doi: 10.1158/1078-0432.CCR-04-2421 CrossRefPubMedGoogle Scholar
  52. 52.
    Sanchez-Munoz A, Garcia-Tapiador AM, Martinez-Ortega E, Duenas-Garcia R, Jaen-Morago A, Ortega-Granados AL, Fernandez-Navarro M, de la Torre-Cabrera C, Duenas B, Rueda AI, Morales F, Ramirez-Torosa C, Martin-Salvago MD, Sanchez-Rovira P (2008) Tumour molecular subtyping according to hormone receptors and HER2 status defines different pathological complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Clin Transl Oncol 10(10):646–653CrossRefPubMedGoogle Scholar
  53. 53.
    Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Leukemia Group BI (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357(15):1496–1506. doi: 10.1056/NEJMoa071167 CrossRefPubMedGoogle Scholar
  54. 54.
    Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP (2006) Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295(14):1658–1667. doi: 10.1001/jama.295.14.1658 PubMedCentralCrossRefPubMedGoogle Scholar
  55. 55.
    Bidard FC, Matthieu MC, Chollet P, Raoefils I, Abrial C, Domont J, Spielmann M, Delaloge S, Andre F, Penault-Llorca F (2008) p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. Ann Oncol 19(7):1261–1265. doi: 10.1093/annonc/mdn039 CrossRefPubMedGoogle Scholar
  56. 56.
    Uhm JE, Park YH, Yi SY, Cho EY, Choi YL, Lee SJ, Park MJ, Lee SH, Jun HJ, Ahn JS, Kang WK, Park K, Im YH (2009) Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer 124(6):1457–1462. doi: 10.1002/ijc.24090 CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Tomi Akinyemiju
    • 1
    Email author
  • Justin Xavier Moore
    • 1
    • 2
  • Sean F. Altekruse
    • 3
  1. 1.Department of EpidemiologyUniversity of Alabama at BirminghamBirminghamUSA
  2. 2.Department of Emergency MedicineUniversity of Alabama School of MedicineBirminghamUSA
  3. 3.Cancer Statistics Branch, Division of Cancer Control and Population SciencesNational Cancer InstituteBethesdaUSA

Personalised recommendations